Neuroinvasion in COVID-19

SARS-CoV-2 presence in the cerebrospinal fluid of COVID-19 patients with acute respiratory failure: a pilot study.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON23627

Enrollment

Registered

2020-04-14

Start date

2020-04-26

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: - At least 18 years of age - Requires mechanical ventilation - Proven SARS-CoV-2 infection - Lumbar puncture possible within 48 hours of ICU admission - Informed consent provided by either patient or legal representative

Exclusion criteria

Exclusion criteria: - Contraindication for lumbar puncture - Proven or suspected cerebrospinal fluid leak or other blood-brain barrier defects - Any condition known to alter cerebrospinal fluid biochemistry - Known or suspected cause for respiratory failure, other than COVID-19 - Any disease known for decreasing pulmonary capacity or compliance

Design outcomes

Primary

Measure	Time frame
SARS-CoV-2 RT-PCR of cerebrospinal fluid	—

Secondary

Measure	Time frame
- 8-week mortality - Leukocyte count of the cerebrospinal fluid - Serum Leukocyte count, C-reactive protein, Lactate dehydrogenase, D-Dimer	—

Contacts

Public ContactFloris Smeets

Zuyderland Medical Centre, Heerlen

fl.smeet@zuyderland.nl088 – 459 9717

Outcome results